Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9901550 | 0.86 | CCR1 (0.56) | CCR1CCR5CCR8HDAC6KDM1A | |
| SCHEMBL9901481 | 0.80 | CCR1 (0.48) | CCR1CCR5CCR8HDAC6KDM1A | |
| SCHEMBL10264656 | 0.75 | CCR1 (0.56) | CCR1CCR5CCR8HDAC6SMN1; SMN2 | |
| SCHEMBL1019002 | 0.74 | MAPT (0.51) | CCR1CCR5CCR8HDAC6SMN1; SMN2 | |
| SCHEMBL16656145 | 0.74 | CCR1 (0.73) | CCR1CCR5CCR8HDAC6SMN1; SMN2 | |
| SCHEMBL439072 | 0.73 | KDM4E (0.43) | CCR1CCR5CCR8HDAC6KDM1A | |
| SCHEMBL28386149 | 0.72 | CCR1 (0.46) | CCR1CCR5CCR8SMN1; SMN2NPC1 | |
| SCHEMBL2482741 | 0.71 | CCR1 (0.60) | CCR1CCR5CCR8HDAC6KDM1A | |
| SCHEMBL31637111 | 0.70 | MAPT (0.46) | SMN1; SMN2NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL15583204 | 0.69 | CCR1 (0.42) | CCR1CCR5CCR8HDAC6KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210669-A1 | COMPOUND FOR THE TREATMENT OF TUMOURS AND TUMOUR METASTASES | SIENA BIOTECH S.P.A. (IT) | 2015-07-30 | — | — | US | disclosed |
| US-20150210669-A1 | COMPOUND FOR THE TREATMENT OF TUMOURS AND TUMOUR METASTASES | SIENA BIOTECH S.P.A. (IT) | 2015-07-30 | — | — | US | disclosed |
| US-20150210669-A1 | COMPOUND FOR THE TREATMENT OF TUMOURS AND TUMOUR METASTASES | SIENA BIOTECH S.P.A. (IT) | 2015-07-30 | — | — | US | disclosed |
| EP-2468726-B1 | Compound for the treatment of tumours and tumour metastases | SIENA BIOTECH SPA (IT) | 2013-08-28 | — | — | EP | disclosed |
| EP-2468726-B1 | Compound for the treatment of tumours and tumour metastases | SIENA BIOTECH SPA (IT) | 2013-08-28 | — | — | EP | disclosed |
| EP-2468726-A1 | Compound for the treatment of tumours and tumour metastases | Siena Biotech S.p.A. (IT) | 2012-06-27 | — | — | EP | disclosed |
| EP-2468726-A1 | Compound for the treatment of tumours and tumour metastases | Siena Biotech S.p.A. (IT) | 2012-06-27 | — | — | EP | disclosed |
| WO-2012076413-A1 | COMPOUND FOR THE TREATMENT OF TUMOURS AND TUMOUR METASTASES | SIENA BIOTECH S.P.A. (IT) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076413-A1 | COMPOUND FOR THE TREATMENT OF TUMOURS AND TUMOUR METASTASES | SIENA BIOTECH S.P.A. (IT) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210669-A1 | COMPOUND FOR THE TREATMENT OF TUMOURS AND TUMOUR METASTASES | SMO, SHH, GLI1 | CCR1 834/4885CCR5 646/4885CCR8 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.